Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Clinical trial NCT05366829 · RECRUITING
Trial details
- NCT number
- NCT05366829
- Sponsor
- Rutgers, The State University of New Jersey
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-25
- Primary completion
- 2027-06-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.